<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A4
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A4
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A4
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lloyd Axelrod, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          ANSWER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incorrect.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          Pioglitazone
         </a>
         , a thiazolidinedione, is not an appropriate medication for the treatment of newly diagnosed type 2 diabetes or for use as a second or third oral agent. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         The thiazolidinediones bind to and modulate the peroxisome proliferator-activated gamma (PPAR-gamma) receptor, a transcription factor, and sensitize patients to the action of insulin. They reduce the glycated hemoglobin (A1C) value by 0.5 to 1.4 percent when used as monotherapy. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         The thiazolidinediones are difficult to use because their effect on glucose levels and A1C values may not be apparent for two to three months. The thiazolidinediones cause weight gain and fluid retention. They should not be used in patients with a history of congestive heart failure or renal insufficiency.
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          Pioglitazone
         </a>
         causes an increased risk of fractures of the upper arms, hands, and feet in female patients with diabetes and may be associated with an increased risk of bladder cancer.
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          Rosiglitazone
         </a>
         , another agent in the same class, may cause an increased risk of myocardial infarction. For all these reasons, thiazolidinediones are not recommended for the initial pharmacologic treatment of diabetes. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'
         </a>
         .)
        </p>
        <p>
         Return to the beginning to try again. (See
         <a class="medical medical_review" href="/z/d/html/4207.html" rel="external">
          "Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes"
         </a>
         .)
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 4248 Version 8.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
